Artificial Intelligence Technology Solutions, Inc. (AITX) announced that its subsidiary Robotic Assistance Devices, Inc. (RAD) has engaged industry veteran Tom Reilly to develop and execute a new channel strategy focused on systems integrators and distributors. This move aims to deepen market penetration and boost sales of RAD's AI-driven security products like RAIA and SARA, which are designed for integration by security partners. Reilly's experience is expected to help RAD build scalable partner programs and support the company's goal of achieving positive operating cash flow by December 2026. The strategy will complement RAD's existing direct sales growth and target large guarding and facility service companies across North America.
Regarding AITX's RAD and its new channel strategy, here is Pluang's Technology sector market snapshot as of Oct 19, 2026 19:31 WIB: Out of 150 priced US Technology stocks tradable on Pluang, 93 rose and 46 fell today. Notable movers include IREN at USD 28.56 with a 5.82% increase and a typical hold time of 29 days, TER at USD 341.36 up 5.03% with a 38-day hold, and ASX at USD 41.49 rising 4.96% with a 49-day hold.
Disc Medicine's stock surged 38% following positive Phase 3 trial results for its drug bitopertin, which showed efficacy and safety in treating erythropoietic protoporphyria. BMO Capital raised its price target from $100 to $120 and maintained an Out...
Qualcomm executive Ann C. Chaplin sold 1,827 shares of the company's stock for $319,268.25 under a Rule 10b5-1 trading plan, reducing her holdings by 6.62%. Qualcomm's stock price recently traded below its 50-day and 200-day moving averages, signalin...
BOK Financial is set to announce its Q3 2026 earnings after market close on October 19, with analysts forecasting earnings per share between $2.52 and $2.54 and revenue near $571 million. The company has a strong history of surpassing earnings estima...
AIBotics has completed the acquisition of NovaCore Labs' assets from PlayJamaica Limited, gaining technology, software, drones, mapping equipment, and customer contracts. This move expands AIBotics' platform in Jamaica and the Caribbean, enhancing AI...
EyePoint's stock dropped sharply after its DURAVYU treatment did not meet the primary endpoint in a Phase 3 trial for wet age-related macular degeneration (wet AMD). Although DURAVYU showed some vision improvement and reduced the need for additional ...
